Anti-inflammatory effects of novel barbituric acid derivatives in T lymphocytes

Zhu, 2009, Differentiation of effector CD4 T cell populations, Annu. Rev. Immunol., 28, 445, 10.1146/annurev-immunol-030409-101212 Steward-Tharp, 2010, New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppression, Ann. N. Y. Acad. Sci., 1183, 123, 10.1111/j.1749-6632.2009.05124.x Smith-Gavin, 2009, T cell activation, Annu. Rev. Immunol., 27, 591, 10.1146/annurev.immunol.021908.132706 Malek, 2010, Interleukin-2 receptor signaling: at the interface between tolerance and immunity, Immunity, 33, 153, 10.1016/j.immuni.2010.08.004 Dong, 2002, MAP kinases in the immune response, Annu. Rev. Immunol., 20, 55, 10.1146/annurev.immunol.20.091301.131133 Crabtree, 1994, Signal transmission between the plasma membrane and nucleus of T lymphocytes, Annu. Rev. Biochem., 63, 1045, 10.1146/annurev.bi.63.070194.005145 Bender, 2006, Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use, Pharmacol. Rev., 58, 488, 10.1124/pr.58.3.5 Conti, 2007, Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling, Annu. Rev. Biochem., 76, 481, 10.1146/annurev.biochem.76.060305.150444 Lerner, 2006, Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies, Biochem. J., 393, 21, 10.1042/BJ20051368 Jin, 2002, Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses, Proc. Natl. Acad. Sci. U. S. A., 99, 7628, 10.1073/pnas.122041599 Huang, 2006, Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD, Curr. Med. Chem., 13, 3253, 10.2174/092986706778773040 Giembycz, 2008, Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?, Br. J. Pharmacol., 155, 288, 10.1038/bjp.2008.297 Spina, 2008, PDE4 inhibitors: current status, Br. J. Pharmacol., 155, 308, 10.1038/bjp.2008.307 Reid, 2012, Roflumilast: a novel treatment for chronic obstructive pulmonary disease, Ann. Pharmacother., 46, 521, 10.1345/aph.1Q646 Man, 2009, Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihy dro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor, J. Med. Chem., 52, 1522, 10.1021/jm900210d Smith, 2003, Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells, Am. J. Phys. Lung Cell. Mol. Phys., 284, L279 Li, 1999, CD3- and CD28-dependent induction of PDE7 required for T cell activation, Science, 283, 848, 10.1126/science.283.5403.848 Smith, 2004, Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes, Mol. Pharmacol., 66, 1679, 10.1124/mol.104.002246 Alaamery, 2010, New classes of PDE7 inhibitors identified by a fission yeast-based HTS, J. Biomol. Screen., 15, 359, 10.1177/1087057110362100 Ivey, 2008, Development of a fission yeast-based high-throughput screen to identify chemical regulators of cAMP phosphodiesterases, J. Biomol. Screen., 13, 62, 10.1177/1087057107312127 Wang, 2005, Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7, J. Biol. Chem., 280, 30949, 10.1074/jbc.M504398200 Ceyhan, 2012, Identification of biologically active PDE11-selective inhibitors using a yeast-based high-throughput screen, Chem. Biol., 19, 155, 10.1016/j.chembiol.2011.12.010 Irizarry, 2003, Exploration, normalization, and summaries of high density oligonucleotide array probe level data, Biostatistics, 4, 249, 10.1093/biostatistics/4.2.249 Gautier, 2004, affy—analysis of Affymetrix GeneChip data at the probe level, Bioinformatics, 20, 307, 10.1093/bioinformatics/btg405 Gentleman, 2004, Bioconductor: open software development for computational biology and bioinformatics, Genome Biol., 5, R80, 10.1186/gb-2004-5-10-r80 Dai, 2005, Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data, Nucleic Acids Res., 33, 10.1093/nar/gni179 Brettschneider, 2008, Quality assessment for short oligonucleotide microarray data, Technometrics, 50, 241, 10.1198/004017008000000334 Benjamini, 1995, Controlling the false discovery rate: a practical and powerful approach to multiple testing, J. R. Stat. Soc. Ser. B, 57, 289 Giembycz, 1996, Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2, Br. J. Pharmacol., 118, 1945, 10.1111/j.1476-5381.1996.tb15629.x Demirbas, 2011, A fission yeast-based platform for phosphodiesterase inhibitor HTSs and analyses of phosphodiesterase activity, Handb. Exp. Pharmacol., 204, 135, 10.1007/978-3-642-17969-3_5 Humar, 2004, Barbiturates directly inhibit the calcium/calcineurin complex: a novel mechanism of inhibition of nuclear factor of activated T cells, Mol. Pharm., 65, 350, 10.1124/mol.65.2.350 Riley, 2002, Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors, Proc. Natl. Acad. Sci. U. S. A., 99, 11790, 10.1073/pnas.162359999 Diehn, 2002, Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation, Proc. Natl. Acad. Sci. U. S. A., 99, 11796, 10.1073/pnas.092284399 Blanco, 2015, Comparative effect of two pan-class I PI3K inhibitors used as anticancer drugs on human T cell function, Int. Immunopharmacol., 28, 675, 10.1016/j.intimp.2015.07.032